Supplemental Disclosures (Tables)

6 Months Ended

Jun. 30, 2026

Payables and Accruals [Abstract]

Schedule of Prepaid Expenses

Prepaid expenses consisted of the following (in thousands):


		June 30, 2026				December 31, 2025
Prepaid external research and development expenses		$	7,957			$	6,410
Prepaid external general and administrative expenses			2,584				3,969
Other			1,363				1,548
		$	11,904			$	11,927

Schedule of Other Current Assets

Other current assets consisted of the following (in thousands):


		June 30, 2026				December 31, 2025
Net cost reimbursement due from AbbVie		$	10,536			$	10,871
Accrued interest on investments			348				1,004
Other			873				1,030
		$	11,757			$	12,905

Schedules of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


		June 30, 2026				December 31, 2025
Accrued personnel costs		$	12,959			$	17,418
Accrued external research and development expenses			6,323				10,229
Accrued external general and administrative expenses			2,028				1,301
Accrued royalties and sublicense fees			964				8,652
Accrued purchases of property and equipment			46				33
Other			753				757
		$	23,073			$	38,390